Talus Bio vs Veeva Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
Seattle AI drug discovery targeting transcription factors with MARMOT platform measuring 10,000 regulomes monthly; YC W21 $11.2M with FDA/EMA Phase I approval for MSD-001 cancer program.
About
Talus Bioscience is a Seattle-based AI-powered drug discovery company targeting transcription factors — the class of proteins historically considered "undruggable" that regulate gene expression and drive many cancers — using its proprietary MARMOT platform (MAssive Regulome Mapping Of Transcriptomes) to measure the binding activity of small molecules across 10,000+ regulomes monthly using live, unmodified human cells. Founded and backed by Y Combinator (W21) with $11.2 million in Seed+ funding raised in August 2024, Talus received FDA and EMA approval for Phase I human trials of its lead program MSD-001 in 2024 — advancing toward first-in-human studies for a transcription factor-targeted cancer therapy.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
About
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.